Web Results
Content Results
  • Biologics for immunosuppression


    Biologics for immunosuppression (often called "biologics" or "biological therapy") are a class of immunosuppressive drugs which chemically are biopharmaceutical treatments. Biologics treat medical conditions where immunotherapy is effective. Some conditions which biologics treat are psoriatic arthritis, rheumatism, and inflammatory bowel disease. Example drugs in this category include adalimumab, certolizumab, etanercept, golimumab, infliximab, belimumab, and ustekinumab.

  • Sanofi


    Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).

  • Dupilumab


    Dupilumab, sold under the trade name Dupixent, is a monoclonal antibody designed for the treatment of allergic diseases such as eczema (atopic dermatitis). Side effects include allergic reactions, cold sores, and inflammation of the cornea. It was developed by Regeneron Pharmaceuticals and Sanofi Genzyme. It received FDA approval for moderate-to-severe atopic dermatitis in 2017. As of 2017 it costs about 37,000 USD per year.

Map Box 1